Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study
Aims: To investigate efficacy and safety of dual therapy with liraglutide and metformin in comparison to glimepiride and metformin, and metformin monotherapy over 2years in patients with type 2 diabetes. Methods: In the 26-week the Liraglutide Effect and Action in Diabetes (LEAD)-2 core trial, patie...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
2013
|
| _version_ | 1797073336549769216 |
|---|---|
| author | Nauck, M Frid, A Hermansen, K Thomsen, AB During, M Shah, N Tankova, T Mitha, I Matthews, D |
| author_facet | Nauck, M Frid, A Hermansen, K Thomsen, AB During, M Shah, N Tankova, T Mitha, I Matthews, D |
| author_sort | Nauck, M |
| collection | OXFORD |
| description | Aims: To investigate efficacy and safety of dual therapy with liraglutide and metformin in comparison to glimepiride and metformin, and metformin monotherapy over 2years in patients with type 2 diabetes. Methods: In the 26-week the Liraglutide Effect and Action in Diabetes (LEAD)-2 core trial, patients (n=1091) were randomized (2:2:2:1:2) to liraglutide (0.6, 1.2 or 1.8mg once-daily), placebo or glimepiride; all with metformin. Patients were enrolled if they were 18-80years old with HbA1c 7.0-11.0% (previous monotherapy ≥3months), or 7.0-10.0% (previous combination therapy ≥3months), and body mass index ≤40kg/m2. Patients completing the 26-week double-blinded phase could enter an 18-month open-label extension. Results: HbA1c decreased significantly with liraglutide (0.4% with 0.6mg, 0.6% with 1.2 and 1.8mg) versus 0.3% increase with metformin monotherapy (p<0.0001). HbA1c decrease with liraglutide was non-inferior versus 0.5% decrease with glimepiride. Liraglutide groups experienced significant weight loss (2.1, 3.0 and 2.9kg with 0.6, 1.2 and 1.8mg, respectively) compared to weight gain (0.7kg) with glimepiride (p<0.0001). Weight loss with liraglutide 1.2 and 1.8mg was significantly greater than with metformin monotherapy (1.8kg; p=0.0185 and p=0.0378 for 1.2 and 1.8mg, respectively). The occurrence of minor hypoglycaemia was <5.0% in all liraglutide groups, significantly less than with glimepiride (24.0%; p<0.0001). Liraglutide was well tolerated overall: gastrointestinal events were more common than with glimepiride or metformin monotherapy, but occurrence decreased with time. Conclusions: Liraglutide provided sustained glycaemic control over 2 years comparable to that provided by glimepiride. Liraglutide was well tolerated, and was associated with weight loss and a low rate of hypoglycaemia. © 2012 Blackwell Publishing Ltd. |
| first_indexed | 2024-03-06T23:20:37Z |
| format | Journal article |
| id | oxford-uuid:6899cafc-c983-4535-acbe-422add498363 |
| institution | University of Oxford |
| last_indexed | 2024-03-06T23:20:37Z |
| publishDate | 2013 |
| record_format | dspace |
| spelling | oxford-uuid:6899cafc-c983-4535-acbe-422add4983632022-03-26T18:45:58ZLong-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 studyJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:6899cafc-c983-4535-acbe-422add498363Symplectic Elements at Oxford2013Nauck, MFrid, AHermansen, KThomsen, ABDuring, MShah, NTankova, TMitha, IMatthews, DAims: To investigate efficacy and safety of dual therapy with liraglutide and metformin in comparison to glimepiride and metformin, and metformin monotherapy over 2years in patients with type 2 diabetes. Methods: In the 26-week the Liraglutide Effect and Action in Diabetes (LEAD)-2 core trial, patients (n=1091) were randomized (2:2:2:1:2) to liraglutide (0.6, 1.2 or 1.8mg once-daily), placebo or glimepiride; all with metformin. Patients were enrolled if they were 18-80years old with HbA1c 7.0-11.0% (previous monotherapy ≥3months), or 7.0-10.0% (previous combination therapy ≥3months), and body mass index ≤40kg/m2. Patients completing the 26-week double-blinded phase could enter an 18-month open-label extension. Results: HbA1c decreased significantly with liraglutide (0.4% with 0.6mg, 0.6% with 1.2 and 1.8mg) versus 0.3% increase with metformin monotherapy (p<0.0001). HbA1c decrease with liraglutide was non-inferior versus 0.5% decrease with glimepiride. Liraglutide groups experienced significant weight loss (2.1, 3.0 and 2.9kg with 0.6, 1.2 and 1.8mg, respectively) compared to weight gain (0.7kg) with glimepiride (p<0.0001). Weight loss with liraglutide 1.2 and 1.8mg was significantly greater than with metformin monotherapy (1.8kg; p=0.0185 and p=0.0378 for 1.2 and 1.8mg, respectively). The occurrence of minor hypoglycaemia was <5.0% in all liraglutide groups, significantly less than with glimepiride (24.0%; p<0.0001). Liraglutide was well tolerated overall: gastrointestinal events were more common than with glimepiride or metformin monotherapy, but occurrence decreased with time. Conclusions: Liraglutide provided sustained glycaemic control over 2 years comparable to that provided by glimepiride. Liraglutide was well tolerated, and was associated with weight loss and a low rate of hypoglycaemia. © 2012 Blackwell Publishing Ltd. |
| spellingShingle | Nauck, M Frid, A Hermansen, K Thomsen, AB During, M Shah, N Tankova, T Mitha, I Matthews, D Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study |
| title | Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study |
| title_full | Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study |
| title_fullStr | Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study |
| title_full_unstemmed | Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study |
| title_short | Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study |
| title_sort | long term efficacy and safety comparison of liraglutide glimepiride and placebo all in combination with metformin in type 2 diabetes 2 year results from the lead 2 study |
| work_keys_str_mv | AT nauckm longtermefficacyandsafetycomparisonofliraglutideglimepirideandplaceboallincombinationwithmetforminintype2diabetes2yearresultsfromthelead2study AT frida longtermefficacyandsafetycomparisonofliraglutideglimepirideandplaceboallincombinationwithmetforminintype2diabetes2yearresultsfromthelead2study AT hermansenk longtermefficacyandsafetycomparisonofliraglutideglimepirideandplaceboallincombinationwithmetforminintype2diabetes2yearresultsfromthelead2study AT thomsenab longtermefficacyandsafetycomparisonofliraglutideglimepirideandplaceboallincombinationwithmetforminintype2diabetes2yearresultsfromthelead2study AT duringm longtermefficacyandsafetycomparisonofliraglutideglimepirideandplaceboallincombinationwithmetforminintype2diabetes2yearresultsfromthelead2study AT shahn longtermefficacyandsafetycomparisonofliraglutideglimepirideandplaceboallincombinationwithmetforminintype2diabetes2yearresultsfromthelead2study AT tankovat longtermefficacyandsafetycomparisonofliraglutideglimepirideandplaceboallincombinationwithmetforminintype2diabetes2yearresultsfromthelead2study AT mithai longtermefficacyandsafetycomparisonofliraglutideglimepirideandplaceboallincombinationwithmetforminintype2diabetes2yearresultsfromthelead2study AT matthewsd longtermefficacyandsafetycomparisonofliraglutideglimepirideandplaceboallincombinationwithmetforminintype2diabetes2yearresultsfromthelead2study |